Catalent, Inc. (CTLT)

NYSE: CTLT · IEX Real-Time Price · USD
58.29
-0.48 (-0.82%)
At close: Feb 26, 2024, 4:00 PM
58.92
+0.63 (1.08%)
After-hours: Feb 26, 2024, 7:48 PM EST
-0.82%
Market Cap 10.55B
Revenue (ttm) 4.10B
Net Income (ttm) -1.30B
Shares Out 180.74M
EPS (ttm) -7.19
PE Ratio n/a
Forward PE 50.17
Dividend n/a
Ex-Dividend Date n/a
Volume 2,389,231
Open 58.65
Previous Close 58.77
Day's Range 58.11 - 59.00
52-Week Range 31.45 - 74.49
Beta 1.20
Analysts Hold
Price Target 52.04 (-10.72%)
Earnings Date Feb 9, 2024

About CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syring... [Read more]

Sector Healthcare
IPO Date Jul 31, 2014
Employees 17,800
Stock Exchange NYSE
Ticker Symbol CTLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for CTLT stock is "Hold." The 12-month stock price forecast is $52.04, which is a decrease of -10.72% from the latest price.

Price Target
$52.04
(-10.72% downside)
Analyst Consensus: Hold
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

NEW YORK , Feb. 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT).  Such investors are advised to conta...

2 days ago - PRNewsWire

CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalent, Inc. (...

10 days ago - Business Wire

Wegovy packing supplier Catalent lays off 300 workers

Catalent has reduced its headcount by about 300 employees as part of its ongoing restructuring plans, the company disclosed in a regulatory filing on Wednesday.

12 days ago - Reuters

Catalent Q2 sales inch past estimates amid takeover by Novo Holdings

Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's paren...

Other symbols: NVO
17 days ago - Reuters

Catalent, Inc. Reports Second Quarter Fiscal 2024 Results

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the s...

17 days ago - Business Wire

Astrazeneca says Catalent deal shows importance of in-house capacity

Astrazeneca on Thursday said the sale of contract drugmaker Catalent to the parent of Novo Nordisk this week demonstrates the importance of building an independent supply chain.

Other symbols: AZN
18 days ago - Reuters

Novo Nordisk CEO on Catalent, Ozempic and Wegovy

Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic. F...

Other symbols: NVO
19 days ago - Bloomberg Markets and Finance

EU watchdog is looking into availability of drugs made at Catalent sites sold to Novo

The European Union's drugs regulator said on Wednesday it will investigate any risks to the availability of medicines processed at Catalent sites that will be sold to Novo Nordisk , part of its mandat...

19 days ago - Reuters

US FDA finds control lapses at Catalent plant being sold to Novo

U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent , including discovery of a "pest" on the manufacturing line, ac...

Other symbols: NVO
20 days ago - Reuters

Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal

Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.

Other symbols: NVO
21 days ago - Investopedia

Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply

Catalent is the main supplier of fill-finish work, which involves filling and packaging syringes and injection pens, for Novo Nordisk's Wegovy.

Other symbols: NVO
21 days ago - CNBC

Shareholder Alert: Ademi LLP investigates whether Catalent, Inc. has obtained a Fair Price in its transaction with Novo Holdings

MILWAUKEE , Feb. 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Catalent (NYSE: CTLT)  for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Holdings. Cl...

21 days ago - PRNewsWire

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Catalent; Is $63.50 a Fair Price?

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Catalent (NYSE:CTLT) breached their fiduciary duties in conn...

21 days ago - Business Wire

CTLT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Catalent, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Catalent, Inc. (NYSE: CTLT) to Novo Holdings for $63.50 per share in cash is fair to Cata...

21 days ago - Business Wire

Wegovy Maker to Boost Production Capacity With Multibillion-Dollar Deal

The controlling shareholder of Wegovy maker Novo Nordisk is buying Catalent in a deal that values the U.S. drug company at $16.5 billion, including debt.

Other symbols: NVO
21 days ago - WSJ

Catalent Stock Jumps on $16.5 Billion Sale to Controlling Shareholder of Ozempic Maker Novo Nordisk

Novo Holdings will acquire Catalent for $63.50 a share in cash.

Other symbols: NVO
21 days ago - Barrons

Novo Holdings to buy Catalent for $11.5 billion to expand Wegovy capacity

Novo Holdings, the holding company of Novo Nordisk , will buy contract drugmaker Catalent in an all-cash transaction worth $11.5 billion in equity value to expand its capacity for popular weight-loss ...

Other symbols: NVO
21 days ago - Reuters

Novo Nordisk's controlling shareholder to buy Catalent for $16.5 billion

Novo Holdings, the controlling shareholder of Novo Nordisk NVO, -1.80%, said it's buying Catalent CTLT, +2.67% for $16.5 billion in cash, or $63.50 per Catalent share, a 16.5% premium to Friday's clos...

Other symbols: NVO
21 days ago - Market Watch

Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction

Bagsværd, Denmark, 5 February 2024 – Novo Nordisk today announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction...

Other symbols: NVO
21 days ago - GlobeNewsWire

Novo Holdings to Acquire Catalent

COPENHAGEN, Denmark & SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a ho...

Other symbols: NVO
21 days ago - Business Wire

Catalent's Indiana plant is filling Wegovy pens to Novo Nordisk for U.S. - ceo

Novo Nordisk's CEO Lars Fruergaard Jorgensen confirmed on Wednesday that Catalent's Indiana plant in the United States has started filling injection pens for its obesity drug Wegovy, helping to boost ...

Other symbols: NVO
26 days ago - Reuters

Catalent, Inc. Announces Second Quarter Fiscal Year 2024 Earnings Conference Webcast

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financ...

4 weeks ago - Business Wire

Catalent Commits to Reducing Greenhouse Gas Emissions by 2030

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced its targets to reduce green...

4 weeks ago - Business Wire

10 Healthcare Stocks That Are Heating Up

The sector has seen one of the best starts to the year in decades, Goldman says.

5 weeks ago - Barrons

Catalent, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executi...

7 weeks ago - Business Wire